Rochester, NY -- (SBWIRE) -- 12/04/2013 -- ARCA biopharma, Inc. (NASDAQ:ABIO) “ABIO” a biopharmaceutical company announced this morning that their GencaroTM Investigational New Drug application for atrial fibrillation has been accepted by the U.S. Food and Drug Administration (FDA) and is now active.
ABIO will now get ready to commence their Phase 2B/3 clinical trial in the first quarter of 2014.
Investors seem to be excited about the FDA news gapping the stock up 15% pre-market. At press time the stock has continued its climb and is up nearly 50%.
ARCA biopharma, Inc. (NASDAQ:ABIO) will probably get a lot of attention over the next few days. The more traders paying attention to a stock the better the chance for price swings smart traders can profit from. The more eyeballs the better. This is especially true for OTC stocks where investor awareness generated buzz creates big price moves every day. To learn how investor awareness campaigns affect stock prices and how to profit from those moves click the link to sign up. IT’S FREE!!
WhisperfromWallStreet has been teaching investors how to trade OTC stocks since 2005. We clearly explain the market dynamics behind most major moves in the OTC markets and provide readers with time tested, easy to follow strategies they can use to stay ahead of the pack.
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)